HOME >> MEDICINE >> NEWS
JCI table of contents: January 19, 2006

DF of this article at: https://www.the-jci.org/article.php?id=24742

OPHTHALMOLOGY
Making new blood vessels: keeping the lines of sight open

The creation of new blood vessels, known as angiogenesis, is a process used to supply oxygen and nutrients at sites of tissue injury. Angiogenesis is known to be stimulated during hypoxia (low oxygen conditions, when new vessels are needed). However, the mechanisms by which hypoxia leads to new vessel formation is poorly understood. In the mouse retina specialized cells called astrocytes regulate angiogenesis by producing a structural support protein known as fibronectin during hypoxia, but until now it was unclear what triggered this pro-angiogenic event. In a new study appearing online on January 19 in advance of print publication in the February 2006 issue of the Journal of Clinical Investigation, Akiyoshi Uemura and colleagues from the RIKEN Center for Developmental Biology in Japan show that a nuclear protein called Tlx in pro-angiogenic astrocytes is regulated by oxygen levels. Mice that were genetically engineered so that they would not express Tlx (known as "Tlx knockout" mice) show a complete absence of retinal blood vessels even though other pro-angiogenic markers are expressed. To determine whether the astrocytes were altered, the authors analyzed fibronectin levels in normal and Tlx knockout mouse retinas. The Tlx knockout astrocytes did not form fibronectin matrices, thus explaining the failure of these mice to undergo retinal angiogenesis. The authors also discovered that Tlx is induced by low oxygen levels and that Tlx gene levels are downregulated during hyperoxia (too much oxygen), revealing that Tlx is an oxygen-sensing switch in retinal astrocytes. Together these studies demonstrate that oxygen-sensing Tlx plays an indispensable role in the development of healthy vascularized retinas via the regulation of formation
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
19-Jan-2006


Page: 1 2 3 4 5 6

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents January

(Date:9/1/2015)... ... ... For many men, the first thing they notice when they go to button their white ... fitting shirt with a collar that doesn’t close against the skin, creating a sloppy look. ... all day because it’s uncomfortable. Now men in suits will be able to do ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( ... fall collection. Every customer who buys an Earth Brand shoe will be given ... with Trees for the Future, a nonprofit dedicated to planting more trees. Earth ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty ... “The Beauty Behind the Fashion” on Thursday, Oct. 1, at the La Valencia ... the spotlight on the collaboration between fashion and professional hair, makeup and nail design. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
Breaking Medicine News(10 mins):Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... 1, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, is scheduled to present at ... Hyatt Regency Boston in Boston, Massachusetts ... Michael A. Mussallem , Edwards Lifesciences, chief executive officer, ... a company discussion with conference attendees at 10:10 a.m. ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
Cached News: